By W. Jorn. Colorado State - Pueblo.
Among combined cases in the stratum of low- and middle-income countries purchase amitriptyline 10 mg with mastercard, the percentage of re-treatment cases was positively correlated quality amitriptyline 10mg, and health expenditure negatively correlated, with both outcome variables. In each stratum, a subanalysis was carried out for the low- and middle-income countries. Another possible reason for the lack of significant contribution of programme indicators could be the lack of reliability or robustness of the programme data. There was only one setting that fell between 3% and 6% – Dashoguz Velayat, Turkmenistan. There were two settings in the African Region; four in the Americas; two in the Eastern Mediterranean; nine in the European Region; two in South- East Asia; and three in the Western Pacific. According to the stem-and-leaf analysis, these are outliers and can be considered as extreme values. Of the ten settings, two showed an important increase (Ivanovo and Tomsk Oblasts); Estonia showed an increase, followed by a decrease; and Latvia showed a decrease, followed by stabilization of prevalence. To take the absolute number correctly into consideration, the sample findings need to be extrapolated. Based on the relative prevalence of the 15 combinations of drug resistance possible with four drugs and the four resistance modes, i. We also try to cast light on the most probable pathways for the creation of drug resistance. Drug susceptibility test results to the four main antituberculosis drugs were obtained for 90 080 cases (77 175 new cases and 12 905 previously treated cases). In order to learn more about drug resistance patterns within the drug-resistant subset of isolates and to be able to compare differences between new and previously treated case groups, due to possible amplification, we also analysed the data taking as denominator the total number of drug- resistant cases in order to determine proportions, which are also expressed as percentages. From analysis of the data using the total number of cases examined as denominator, we can make the following general statements: • Among new cases, the most frequent drug-resistant types globally are H (3. From the analysis of the data using the total number of drug-resistant cases as denominator, we can make the following general statements: • Among new cases globally, monoresistance represented the majority of the drug resistance problem (60. The proportions of triple and quadruple resistance have been combined to facilitate interpretation. The last four were under the coordination of the Mycobacteriology Unit of the Prince Léopold Institute of Tropical Medicine, Antwerp, Belgium. The following results reflect the overall performance of all laboratories that took part in this proficiency testing exercise from 1994 to 2002. The cumulative sensitivity was 99% for isoniazid, 98% for rifampicin, and 91% for both streptomycin and ethambutol. The cumulative specificity was 98% for both rifampicin and isoniazid, 93% for ethambutol, and 91% for streptomycin. Efficiencies of 100% were found for rifampicin and isoniazid, 97% for ethambutol, and 92% for streptomycin. Intralaboratory reproducibility of results in the two identical pairs of 10 isolates tested was 98% for isoniazid and rifampicin, 96% for ethambutol, and 91% for streptomycin. The number of countries participating in the project has increased nearly threefold since the first report. Performance criteria for the Supranational Laboratory Network have been developed, four new laboratories are candidates to join, and nine rounds of proficiency testing have been completed. Guidelines for the surveillance of drug resistance in tuberculosis have been revised, and a fourth version of software to analyse drug resistance has been developed. Most importantly, global results of the project are fuelling discussions about policy implications. The areas represented in this project are those with at least the minimum requirements to conduct surveillance, and it is likely that the worst situations have not yet been uncovered. The data reported in this third phase of the Project have reinforced many of the conclusions drawn in its first and second reports, and contribute to a more in-depth analysis of dynamics and trends. Despite the inclusion of different countries in each phase of the project, the medians for most resistance parameters were similar in all reports, but the outliers varied. Though the Global Project has been operating since 1994 very few countries have reported data for all nine years. Data from repeated surveys employing comparable methodologies over several years are essential to determine with any certainty in which direction prevalence of drug resistance is moving. A better programme can result in the reduction of the overall number of re-treated cases; however, difficult (resistant) cases may persist. Improvement in laboratory proficiency, particularly the sensitivity and specificity of drug susceptibility testing, may also affect the observed prevalence of resistance. The scenarios outlined above highlight the importance of evaluating trends in prevalence of drug resistance within the context of relevant programme developments. Only Botswana, Sierra Leone, and Mpumalanga Province, South Africa, have carried out repeat surveys. In general, drug resistance in the region is low, but the trends in Botswana and Mpumalanga Province in South Africa indicate that it is increasing. Botswana in particular showed a significant increase in prevalence of any resistance. Sierra Leone, with two data points in the first and second reports, showed very little change in prevalence of resistance.
Treatment success is discount amitriptyline 75mg with visa, in part generic amitriptyline 50mg on-line, a variable of the time between the onset of symptoms and the beginning of antiviral treatment: the sooner after onset treatment begins, the better. The neuraminidase inhibitors, oseltamivir and zanamivir, have fewer side effects than the M2 ion channel inhibitors rimantadine and amantadine, and drug resistance seems to develop less frequently. The clinical pharmacology, adverse effects and resistance profiles of these drugs are discussed in detail in the Drugs chapter. Neuraminidase Inhibitors These drugs – introduced in 1999 and 2000 – interfere with the normal function of the influenza neuraminidase by mimicking sialic acid, the natural substrate of the Antiviral Drugs 171 neuraminidase (Varghese 1992, Varghese 1995). The viral neuraminidase is re- sponsible for cleaving sialic acid residues on newly formed virions, playing an es- sential role in their release and facilitating virus spread within the respiratory tract. When exposed to neuraminidase inhibitors, the influenza virions aggregate on the surface of the host cell, limiting the extent of infection within the mucosal secre- tions (McNicholl 2001) and reducing viral infectivity (see Figure at http://content. Experimental evidence further suggests that influenza neuraminidase may be essential at the early stage of virus invasion of the ciliated epithelium of human airways (Matrosovich 2004). The design of the neuraminidase inhibitors was a result of the analysis of the three- dimensional structure of influenza neuraminidase which disclosed the location and structure of the catalytic site (Colman 1983). Numerous treatment studies in healthy adults have shown that neuraminidase in- hibitors, when taken within 36 to 48 hours after the onset of symptoms, decrease the symptomatic illness by one or two days (Hayden 1997, Monto 1999, Treanor 2000, Nicholson 2000, Hedrick 2000, Cooper 2003, Whitley 2001, Aoki 2003). When started within the first 12 hours following the onset of fever, neuraminidase inhibitors shortened the illness by more than three days, in comparison to treatment that was started at 48 hours. The duration of fever, severity of symptoms, and time to return to normal activity also correlated with the time of initiation of antiviral intervention. A study in Canadian long-term care facilities showed that older nursing home resi- dents who were treated with oseltamivir within 48 hours after the onset of symp- toms were less likely to be prescribed antibiotics, to be hospitalised, or to die (Bowles 2002). Another study sug- gested that oseltamivir treatment of influenza illness reduces lower respiratory tract complications, antibiotic use, and hospitalisation in both healthy and “at-risk” adults (Kaiser 2003). Prevention trials have shown that neuraminidase inhibitors administered prophy- lactically reduce the risk of developing influenza by 60-90 % when given at the start of the influenza outbreak (Monto 1999b, Cooper 2003). When administered prophylactically to household contacts of an influenza index case, protective effi- cacy against clinical influenza was generally > 80 % (Hayden 2000, Kaiser 2000, Welliver 2001, Monto 2002). In par- ticular, the observed safety profile of oseltamivir and zanamivir compares favoura- bly with the M2 inhibitors rimantadine and amantadine (Freund 1999, Doucette 2001). Zanamivir is therefore not generally recommended for the treatment of patients with underly- 172 Treatment and Prophylaxis ing airways disease, and should also be discontinued in patients who develop bron- chospasm or who have a decline in respiratory function (Relenza 2003). In oseltamivir, competitive inhibition of excretion by the renal tubular epithelial cell anionic transporter may occur. Naturally occurring virus strains resistant to neuraminidase inhibitors are believed not to exist in human influenza A (McKimm-Breschkin 2003). However, a recent report describes a resistant H5N1 strain carry- ing the H274Y mutation causing viremia in two patients who subsequently died from avian influenza (de Jong 2005). Zanamivir seems to retain in vitro activity against some oseltamivir-resistant strains (McKimm-Breschkin 2003, Mishin 2005). Following clinical use, the incidence of development of resistant strains is lower among adults and adolescents older than 13 years, than among children. These findings are reason for concern, since children are an important transmission vector for the spread of influenza virus in the community. In the case of an H5N1 pandemic, the frequency of resistance emergence during osel- tamivir treatment of H5N1 paediatric patients is uncertain, but it is likely to be no less than that observed in children infected with currently circulating human influ- enza viruses (Hayden 2005). Neuraminidase inhibitors are effective against the virus that caused the 1918 pan- demic (Tumpey 2002). Indications for the Use of Neuraminidase Inhibitors ® ® Oseltamivir (Tamiflu ) and zanamivir (Relenza ) are currently licensed for the treatment of influenza A and B. They should be used only when symptoms have occurred within the previous 48 hours and should ideally be initiated within 12 hours of the start of illness. In addition, oseltamivir – but not zanamivir (with the exception of two countries) – is also licensed for prophylaxis when used within 48 hours of exposure to influ- enza and when influenza is circulating in the community; it is also licensed for use in exceptional circumstances (e. Oseltamivir and zanamivir seem to have similar efficacy, but they differ in their modes of delivery and tolerability. Zanamivir is delivered by inhalation and is well tolerated; however, children, especially those under 8 years old, are usually unable to use the delivery system appropriately and elderly people may have difficulties, too (Diggory 2001). Antiviral Drugs 173 M2 Ion Channel Inhibitors Amantadine and rimantadine are tricyclic symmetric adamantanamines. They are active only against influenza A virus (influenza B does not possess an M2 protein), have more side effects than neuraminidase inhibitors, and may select for readily transmissible drug-resistant viruses. M2 inhibitors block an ion channel formed by the M2 protein that spans the viral membrane (Hay 1985, Sugrue 1991) and is required for viral uncoating (for more details see the Drugs chapter). Both drugs are effective as treatment if started within 24 hours of illness onset, reducing fever and symptoms by 1–2 days (Wing- field 1969, Smorodintsev 1970, van Voris 1981). Daily prophylaxis during an influenza season reduces infection rates by 50–90 % (Dawkins 1968, Dolin 1982, Clover 1986).
The role of endo-bronchial ultrasound and biopsy of mediastinal nodes for staging of the disease is discussed in Chapter 3 on referral and diagnosis purchase 25 mg amitriptyline fast delivery, and choice of radiological test and biopsy technique are covered in Chapter 4 proven 10 mg amitriptyline. It is essential to have a fully represented team participating in decision making to ensure that state-of-the-art treatment is offered to patients with the best chance of an improved outcome. The need for data collection to measure outcomes is stressed in Chapter 7, and the collection thereof, in particular the clinical data, remains the responsibility of the members of the multidisciplinary team, with support from a data manager. A summary of key information and guidance for staff dealing with patients and giving diagnoses of cancer is provided in Chapter 8. In Chapter 9, guidance is given for ways of achieving good communication with patients and professionals in primary care and the community. In Chapter 10, recommendations are made regarding requirements of a high-quality surgical service and how these standards can be measured. For more advanced, but potentially curable disease other radical treatments are described in Chapter 12 using concomitant or sequential chemo-radiotherapy or radiotherapy alone, and recommendations are made for follow-up of this group. The management of small cell lung cancer, Chapter 14, is largely unchanged, though there are recommendations for oral topotecan second line. The role of the nurse in providing information for patients and carers so that they can cope with the illness, and then deal with the consequences and long term side effects of the treatment as survivors is also discussed. As the majority of patients with lung cancer present with their disease in an advanced stage, palliative treatment of these patients is important to improve their quality of life, and in Chapter 17 this is considered in some detail, particularly in relation to some advances in specific therapies. During the coming months the clinicians will develop standards and measures against which organisations can be assessed. Measures to prevent people from taking up smoking, or helping them to quit, will reduce the number of deaths from lung cancer. In addition, patients with lung cancer undergoing curative treatment who stop smoking pre-treatment reduce the risk of complications from surgery. Rates are higher in males than females and in more socio-economic deprived groups. Incidence rates of lung cancer closely reflect past smoking prevalence with a time lag of approximately 20 to 30 years. Smoking prevalence has decreased over the past 50 years and this accounts for the decrease in the rates of lung cancer. The provision of effective smoking cessation services in an acute Trust setting remains highly variable despite evidence that delivering smoking cessation interventions to inpatients in hospital is effective (Rigotti et al. This is clearly a missed opportunity to deliver stop smoking interventions at a point at which an individual may be more susceptible to health advice and hence more motivated to quit. The key document for acute Trusts is Stop Smoking Interventions in Secondary Care. The main barriers to successful implementation tend to be administrative elements such as data collection. Lack of support from the Trust was also commonly cited as a barrier to implementing interventions. Smoking cessation interventions must be targeted to reach different population groups and provided across a range of settings. In particular, there has been an increased focus on the need to establish effective smoking cessation services in secondary care (Fiore et al. It is advisable for patients undergoing surgery to have ceased smoking for a month before the operation rather than immediately beforehand, though it is not recommended that surgery is delayed because patients continue to smoke. There are suggestions that other treatments for lung cancer are more effective if patients are no longer smoking, and for patients who have undergone radical treatment it may reduce the risk of a second tumour. Patients from the age of 16 to the end of their 18th year should be treated in a principal treatment centre (see Appendix 10 for contact details of principal treatment centres). Teenagers and young adults in this age group should be treated either in the principal treatment centre or a designated hospital. Direct referrals from radiology are seen according to each unit’s agreed operational policy. The patient is contacted initially by phone and then by letter if telephone contact cannot be made, with an explanation of why they need to be seen urgently. Investigations should be selected to offer the most diagnostic information with the least risk of harm. Where there is evidence of distant metastases, then biopsies should be taken from the metastatic site if this can be achieved more easily than from the primary site. If patients have a previous diagnosis of cancer, this should influence where the biopsy is taken from to distinguish between primary and metastatic lung cancer. Patients who are on oral anti-coagulants and new anti-platelet agents should be offered a risk assessment of the safety of discontinuing these drugs, and if necessary a second opinion should be obtained, prior to any biopsy. In some cases where anti-coagulants need to be continued, low molecular weight heparins can be substituted. As yet there is no national guidance regarding management of oral anti-platelet agents for lung biopsies.
10 of 10 - Review by W. Jorn
Votes: 113 votes
Total customer reviews: 113